nach oben

Current Oncology Reports

Erschienen in:

01.05.2017 | Leukemia (A Aguayo, Section Editor)

Philadelphia-Like Acute Lymphoblastic Leukemia in Adults

verfasst von: Tobias Herold, Nicola Gökbuget

Erschienen in: Current Oncology Reports | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

This study aims to provide an overview of the classification, incidence, genomic alterations, and clinical implications of Philadelphia-like Acute Lymphoblastic Leukemia (Ph-like ALL) in adults.

Recent findings

Ph-like ALL is a high-risk subtype of B cell precursor ALL with characteristic genomic alterations in children and adults. A standard approach for diagnosis is missing and currently mainly based on gene expression analysis. The incidence is age depended and highest in adolescents and younger adults (age 16–39) where 19–28% of patients belong to this subtype. Ph-like ALL is associated with persistence of minimal residual disease (MRD) and inferior prognosis. Some genomic alterations respond to specific treatment approaches and provide hope for tailored therapies.

Summary

Ph-like ALL in adults is an aggressive and high-risk subtype of B cell precursor ALL. Without consensus definition, diagnosis is difficult and current publications highlight the importance of stringent MRD monitoring to guide risk-adapted treatment strategies.

Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013;381(9881):1943–55. doi:10.1016/S0140-6736(12)62187-4.CrossRefPubMed

Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29(5):532–43. doi:10.1200/JCO.2010.30.1382.CrossRefPubMed

Gokbuget N. How I, treat older patients with ALL. Blood. 2013;122(8):1366–75. doi:10.1182/blood-2012-07-379016.CrossRefPubMed

Brissot E, Labopin M, Beckers MM, Socie G, Rambaldi A, Volin L, et al. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica. 2015;100(3):392–9. doi:10.3324/haematol.2014.116954.CrossRefPubMedPubMedCentral

Fielding AK, Rowe JM, Buck G, Foroni L, Gerrard G, Litzow MR, et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 2014;123(6):843–50. doi:10.1182/blood-2013-09-529008.CrossRefPubMedPubMedCentral

Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5):470–80. doi:10.1056/NEJMoa0808253.CrossRefPubMedPubMedCentral

Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10(2):125–34. doi:10.1016/S1470-2045(08)70339-5.CrossRef

Boer JM, Marchante JR, Evans WE, Horstmann MA, Escherich G, Pieters R, et al. BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures. Haematologica. 2015;100(9):e354–7. doi:10.3324/haematol.2015.124941.CrossRefPubMedPubMedCentral

Boer JM, Koenders JE, van der Holt B, Exalto C, Sanders MA, Cornelissen JJ, et al. Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates. Haematologica. 2015;100(7):e261–4. doi:10.3324/haematol.2014.117424.CrossRefPubMedPubMedCentral

10.

Harvey RC, Mullighan CG, Chen IM, Wharton W, Mikhail FM, Carroll AJ, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood. 2010;115(26):5312–21. doi:10.1182/blood-2009-09-245944.CrossRefPubMedPubMedCentral

11.

Hunger SP, Mullighan CG. Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood. 2015;125(26):3977–87. doi:10.1182/blood-2015-02-580043.CrossRefPubMedPubMedCentral

12.

Jain N, Roberts KG, Jabbour E, Patel K, Eterovic AK, Chen K, et al. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. Blood. 2017;129(5):572–81. doi:10.1182/blood-2016-07-726588.CrossRefPubMed

13.

Kang H, Roberts KG, Chen I-ML, Atlas SR, Bedrick EJ, Gastier-Foster JM, et al. Development and validation of a highly sensitive and specific gene expression classifier to prospectively screen and identify B-precursor acute lymphoblastic leukemia (ALL) patients with a Philadelphia chromosome-like (“Ph-like” or “BCR-ABL1-like”) signa…. Blood. 2013;122(21):826.

14.

Fasan A, Kern W, Nadarajah N, Weber S, Schindela S, Schlenther N, et al. Three steps to the diagnosis of adult Ph-like ALL. Blood. 2015;126(23):2610.

15.

• Herold T, Schneider S, Metzeler K, Neumann M, Hartmann L, Roberts KG, et al. Philadelphia chromosome-like acute lymphoblastic leukemia in adults have frequent IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis. Haematologica. 2016. doi:10.3324/haematol.2015.136366. First comprehensive analysis of homogeneously and intensively treated adult and older adult Northern European Ph-like ALL patients using the St. Jude classification algorithm.

16.

Ofran Y, Izraeli S. BCR-ABL (Ph)-like acute leukemia—pathogenesis, diagnosis and therapeutic options. Blood Rev. 2016. doi:10.1016/j.blre.2016.09.001.PubMed

17.

Herold T, Baldus CD, Gokbuget N. Ph-like acute lymphoblastic leukemia in older adults. N Engl J Med. 2014;371(23):2235. doi:10.1056/NEJMc1412123#SA1.CrossRefPubMed

18.•

Roberts KG, Gu Z, Payne-Turner D, McCastlain K, Harvey RC, Chen IM, et al. High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults. J Clin Oncol. 2017;35(4):394–401. doi:10.1200/JCO.2016.69.0073. Landmark publication of more than 700 adult ALL patients with extensive molecular characterisation of the Ph-like subgroup.CrossRefPubMed

19.••

Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005–15. doi:10.1056/NEJMoa1403088. Landmark publication of more than 1700 ALL patients (children, adolescents and young adults) with extensive molecular characterisation of the Ph-like subgroup. Furthermore, the study demonstrated the responsiveness of several uncovered translocations to targeted treatment approaches.CrossRefPubMedPubMedCentral

20.

Tasian SK, Hurtz C, Wertheim GB, Bailey NG, Lim MS, Harvey RC, et al. High incidence of Philadelphia chromosome-like acute lymphoblastic leukemia in older adults with B-ALL. Leukemia. 2017. doi:10.1038/leu.2016.375.PubMed

21.

Maude SL, Tasian SK, Vincent T, Hall JW, Sheen C, Roberts KG, et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood. 2012;120(17):3510–8. doi:10.1182/blood-2012-03-415448.CrossRefPubMedPubMedCentral

22.

Richmond J, Robbins A, Evans K, Beck D, Kurmasheva RT, Billups CA, et al. Acute sensitivity of Ph-like acute lymphoblastic leukemia to the SMAC-mimetic birinapant. Cancer Res. 2016;76(15):4579–91. doi:10.1158/0008-5472.CAN-16-0523.CrossRefPubMed

23.

Churchman ML, Low J, Qu C, Paietta EM, Kasper LH, Chang Y, et al. Efficacy of retinoids in IKZF1-mutated BCR-ABL1 acute lymphoblastic leukemia. Cancer Cell. 2015;28(3):343–56. doi:10.1016/j.ccell.2015.07.016.CrossRefPubMedPubMedCentral

24.

Yano M, Imamura T, Asai D, Kiyokawa N, Nakabayashi K, Matsumoto K, et al. Identification of novel kinase fusion transcripts in paediatric B cell precursor acute lymphoblastic leukaemia with IKZF1 deletion. Br J Haematol. 2015;171(5):813–7. doi:10.1111/bjh.13757.CrossRefPubMed

25.

Kobayashi K, Miyagawa N, Mitsui K, Matsuoka M, Kojima Y, Takahashi H, et al. TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation. Pediatr Blood Cancer. 2015;62(6):1058–60. doi:10.1002/pbc.25327.CrossRefPubMed

26.

Tomita O, Iijima K, Ishibashi T, Osumi T, Kobayashi K, Okita H, et al. Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1. Leuk Res. 2014;38(3):361–70. doi:10.1016/j.leukres.2013.11.017.CrossRefPubMed

27.

Masuzawa A, Kiyotani C, Osumi T, Shioda Y, Iijima K, Tomita O, et al. Poor responses to tyrosine kinase inhibitors in a child with precursor B-cell acute lymphoblastic leukemia with SNX2-ABL1 chimeric transcript. Eur J Haematol. 2014;92(3):263–7. doi:10.1111/ejh.12234.CrossRefPubMed

28.

Kobayashi K, Mitsui K, Ichikawa H, Nakabayashi K, Matsuoka M, Kojima Y, et al. ATF7IP as a novel PDGFRB fusion partner in acute lymphoblastic leukaemia in children. Br J Haematol. 2014;165(6):836–41. doi:10.1111/bjh.12834.CrossRefPubMed

29.

Weston BW, Hayden MA, Roberts KG, Bowyer S, Hsu J, Fedoriw G, et al. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. J Clin Oncol. 2013;31(25):e413–6. doi:10.1200/JCO.2012.47.6770.CrossRefPubMed

30.

Heizmann B, Kastner P, Chan S. Ikaros is absolutely required for pre-B cell differentiation by attenuating IL-7 signals. J Exp Med. 2013;210(13):2823–32. doi:10.1084/jem.20131735.CrossRefPubMedPubMedCentral

31.

Roberts KG, Pei D, Campana D, Payne-Turner D, Li Y, Cheng C, et al. Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol. 2014;32(27):3012–20. doi:10.1200/JCO.2014.55.4105.CrossRefPubMedPubMedCentral

32.

Topp MS, Gokbuget N, Zugmaier G, Degenhard E, Goebeler ME, Klinger M, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120(26):5185–7. doi:10.1182/blood-2012-07-441030.CrossRefPubMed

33.

Topp MS, Gokbuget N, Stein AS, Zugmaier G, O’Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57–66. doi:10.1016/S1470-2045(14)71170-2.CrossRefPubMed

34.

Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–53. doi:10.1056/NEJMoa1509277.CrossRefPubMed

35.

Piccaluga PP, Arpinati M, Candoni A, Laterza C, Paolini S, Gazzola A, et al. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk Lymphoma. 2011;52(2):325–7. doi:10.3109/10428194.2010.529206.CrossRefPubMed

36.

Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Long-term outcomes after blinatumomab treatment: follow-up of a phase 2 study in patients (Pts) with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukemia (ALL). Blood. 2015;126(23):680.

37.

Duhoux FP, Auger N, De Wilde S, Wittnebel S, Ameye G, Bahloula K, et al. The t(1;9)(p34;q34) fusing ABL1 with SFPQ, a pre-mRNA processing gene, is recurrent in acute lymphoblastic leukemias. Leuk Res. 2011;35(7):e114–7. doi:10.1016/j.leukres.2011.02.011.CrossRefPubMed

38.

Lilljebjorn H, Agerstam H, Orsmark-Pietras C, Rissler M, Ehrencrona H, Nilsson L, et al. RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSF1R fusion responsive to imatinib. Leukemia. 2014;28(4):977–9. doi:10.1038/leu.2013.324.CrossRefPubMed

39.

Imamura T, Kiyokawa N, Kato M, Imai C, Okamoto Y, Yano M, et al. Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan. Blood Cancer J. 2016;6:e419. doi:10.1038/bcj.2016.28.CrossRefPubMedPubMedCentral

Titel: Philadelphia-Like Acute Lymphoblastic Leukemia in Adults
verfasst von: Tobias Herold
Nicola Gökbuget
Publikationsdatum: 01.05.2017
Verlag: Springer US
Erschienen in: Current Oncology Reports / Ausgabe 5/2017
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-017-0589-2

Springer Medizin

Philadelphia-Like Acute Lymphoblastic Leukemia in Adults

Abstract

Purpose of review

Recent findings

Summary

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose of review

Recent findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2017

The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer

Adjuvant Therapy for Melanoma

Emerging Variants of Castration-Resistant Prostate Cancer

Optimal Therapy for Early-Stage Hodgkin’s Lymphoma: Risk Adapting, Response Adapting, and Role of Radiotherapy

Immunotherapy for Esophageal Squamous Cell Carcinoma

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie